Today on MedNet21, we're going to discuss Heart Failure: Medical Management.
Learners should expect to learn about 2 new medical management options for heart failure including
sacubitril-valsartan and ivabradine. They should understand the mechanisms, indications, and
contraindications of these drugs. The pivotal trials for each new therapy will be discussed and more recent updated research data will be reviewed.
Dates and Times
End Date: 1/31/2023
ObjectivesAs a result of this educational activity, webcast participants will be able to: UNDERSTAND the mechanism of action and indications for sacubitril-valsartan; UNDERSTAND the mechanism of action and indications for ivabradine; DISCUSS the pharmacological management of heart failure; and RECOGNIZE new heart failure therapies including sacubitril-valsartan and ivabradine as well as understand their role in treating heart failure.
The Center for Continuing Medical Education (CCME) at The Ohio State University is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians
The Center for Continuing Medical Education (CCME) at The Ohio State University designates this webcasts for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.